Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics strengthens clinical research team with senior appointments

Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science
picture of handshake
Allergy is strengthening its clnical research team

Allergy Therapeutics plc (LON:AGY) has strengthened its clinical research team with two senior appointments.

Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science.

At his previous firm, Dutch firm HAL Allergy, de Kam was in charge of clinical development for pollen and dust mites, two key product development areas for Allergy.

Allergy Therapeutics revenues rise as hay fever portfolio cleans up

Piggot, meanwhile, has significant experience of taking respiratory development programs through Phase I to IV trials and will be responsible for the delivery of Allergy's clinical strategy and products pipeline.

In addition, Tim Higenbottam has been appointed to the position of senior pharmaceutical physician and will focus on the US regulatory process.

Murray Skinner, Allergy’s chief scientific officer of Allergy Therapeutics, said the trio’s vast experience and expert knowledge was ideal to help bring new and convenient into the allergy immunotherapy market."

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

Woman stroking face
October 03 2017
Its SkinBiotix cream was assessed for cellular toxicity
worried man on bed
October 16 2017
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use